Clinical trials: Endocrine Disorder
Diabetes Mellitus, Type 2
An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)
The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT00094757
- Testing
- Comparator: sitagliptin 100 mg, Comparator: sitagliptin 200 mg, Comparator: pioglitazone
- Volunteers
- 521 people
- Sponsor
- Merck Sharp & Dohme LLC
Acromegaly
Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors…
- Trial name
- NCT00658879
- Testing
- Somavert (Pegvisomant)
- Volunteers
- 251 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2, Hypertension
Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents
The purpose of this study is to evaluate the effect of canagliflozin (JNJ-28431754) on blood pressure reduction, compared to placebo, in patients with hypertension and type 2 diabetes mellitus and who are on stable doses of…
- Trial name
- NCT01939496
- Testing
- Canagliflozin
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 171 people
- Sponsor
- Janssen Scientific Affairs, LLC
Type 2 Diabetes
An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets
The purpose of this clinical research study is to learn if initiating treatment with BMS-51248 (Dapagliflozin) in combination with metformin XR can improve diabetes control in patients with Type 2 Diabetes who do not receive any…
- Trial name
- NCT00643851
- Testing
- Dapagliflozin, Metformin XR
- Where
- 99 sites in United States, Mexico and 5 more
- Volunteers
- 994 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)
This is a dose-ranging study that will evaluate the efficacy, safety and tolerability of a range of doses of investigational product and pioglitazone, compared to placebo, administered as monotherapy over 12 weeks in treatment…
- Trial name
- NCT00500331
- Testing
- GSK189075, pioglitazone
- Where
- 136 sites in United States, Argentina and 17 more
- Volunteers
- 334 people
- Sponsor
- GlaxoSmithKline
Diabetic Neuropathy, Painful; Diabetic Neuropathies
Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability
This is a 2-part study. In Part 1 of the study, subjects will undergo a pain reporting training program in which a painful stimulus will be applied to the subject's hand, and the subjects will be asked to report how painful the…
- Trial name
- NCT01928381
- Testing
- AZD5213 + pregabalin, pregabalin capsules
- Where
- 9 sites in United States
- Volunteers
- 150 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, Coronary Artery Disease
Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus
Recent studies have shown that withdrawing aspirin and maintaining P2Y12 inhibitor monotherapy for up to 12 months post-PCI, after a brief period of DAPT, reduces bleeding without increasing ischemic harm.
- Trial name
- OPTIMUS-7 (NCT04484259)
- Testing
- Ticagrelor monotherapy, Ticagrelor plus aspirin, Clopidogrel with aspirin
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- University of Florida
Peer Support and Chronic Disease, Obesity
Peer Support Dyads in Churches
The purpose of this study is to explore how working with a partner can influence participation in a church wellness program. There are many different types of church wellness programs.
- Conditions
- Peer Support and Chronic Disease, Obesity, Type II Diabetes, Cardiovascular Disease
- Trial name
- NCT03463941
- Testing
- Peer Support Dyad Intervention
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Duke University
Diabetes Mellitus
Glycemic Optimization On Discharge From the Emergency Room
Continuous glucose monitors can help people with diabetes avoid blood sugar levels that are either dangerously high or low. This study evaluates whether continuous glucose monitoring after discharge from the emergency room can…
- Trial name
- GOOD-ER (NCT05197829)
- Testing
- Continuous Glucose Monitoring, Care Coordination
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Mark O'Connor
Pancreatic Cancer
SBRT Plus Pembrolizumab and Trametinib for Pancreatic Cancer
Hypothesis: Survival benefits could be found in SBRT Plus Pembrolizumab and Trametinib compared with SBRT plus gemcitabine.
- Trial name
- NCT02704156
- Testing
- Cyberknife plus Pembrolizumab and Trametinib, Cyberknife plus Gemcitabine
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Changhai Hospital
Hyperparathyroidism, Hypercalcemia
Studies of Elevated Parathyroid Activity
Observational Phase: Patients whose parathyroid activity is elevated above normal are referred to as having hyperparathyroidism.
- Conditions
- Hyperparathyroidism, Hypercalcemia, Parathyroid Neoplasm, Multiple Endocrine Neoplasia
- Trial name
- NCT00001277
- Testing
- 68Ga-Dotatate, 18F-DOPA
- Where
- United States
- Volunteers
- 1,553 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Atherosclerosis, Cardiovascular Disease
Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk
The hypothesis is that salsalate therapy may be an effective and safe method to modulate inflammation in metabolically-critical tissues and thus reduce insulin resistance and its related complications.
- Conditions
- Atherosclerosis, Cardiovascular Disease, Inflammation, Insulin Resistance
- Trial name
- NCT00330733
- Testing
- Salsalate
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- VA Office of Research and Development
Pancreatic Ductal Carcinoma
A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
The purpose of this study is to compare the efficacy and safety of PEGylated Recombinant Human Hyaluronidase (PEGPH20) combined with nab-paclitaxel plus gemcitabine (PAG treatment), compared with placebo combined with…
- Trial name
- NCT02715804
- Testing
- Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20), nab-Paclitaxel, Gemcitabine
- Where
- 217 sites in United States, Australia and 20 more
- Volunteers
- 492 people
- Sponsor
- Halozyme Therapeutics
Diabetes Mellitus, Type 2
A Study of Postprandial Hyperglycemia in Participants With Type 2 Diabetes
This Study is looking at whether high blood glucose levels after a meal affect arterial stiffness more or less than low blood glucose levels, and whether certain cardiovascular markers influence the outcome of this.
- Trial name
- NCT01159938
- Testing
- Lispro
- Where
- Finland
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Pancreatic Cancer
Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00100815
- Testing
- bevacizumab, capecitabine, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Roswell Park Cancer Institute
Heart Failure, Coronary Artery Disease
COVID-19 Testing in Underserved and Vulnerable Populations
As part of National Institutes of Health Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) program, the goal of the RADxUP study is to develop, test, and evaluate a rapid, scalable capacity building project to…
- Conditions
- Heart Failure, Coronary Artery Disease, Cancer, Chronic Kidney Diseases
- Trial name
- NCT05315908
- Testing
- Community outreach method
- Where
- United States
- Volunteers
- 9,120 people
- Sponsor
- Jesse Nodora
Type II Diabetes
Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes
The purpose of this study is to assess the 1 month safety and tolerability after multiple oral doses of AZD1656 in patients with Type 2 Diabetes Mellitus Treated with Insulin
- Trial name
- NCT00856908
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
A Study on the Effect of 2 Pen Devices on HbA1c
The purpose of this study is to test the hypothesis that the HumaPen Memoir with memory function, when used over 24 weeks for prandial insulin injections achieves superior glycemic control, when compared to the conventional…
- Trial name
- NCT00985712
- Testing
- Insulin Lispro, Huminsulin Regular, HumaPen Memoir
- Where
- 29 sites in Germany
- Volunteers
- 263 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2, Patient Discharge
Effectiveness of a Diabetes Focused Discharge Order Set Among Poorly Controlled Hospitalized Patients Transitioning to Glargine U300 Insulin
Diabetes is present in 25% of hospitalized patients; yet effective hospital discharge programs for patients with diabetes are understudied.
- Conditions
- Diabetes Mellitus, Type 2, Patient Discharge, Blood Glucose, Low, Blood Glucose, High
- Trial name
- NCT03455985
- Testing
- Discharge Order Set (DOS), Enhanced Standard Care (ESC)
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- Ohio State University
Type 2 Diabetes
A Study of LY3437943 in Participants With Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of…
- Trial name
- NCT04867785
- Testing
- LY3437943, Dulaglutide
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 281 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.